OOIR: Observatory of International Research

Papers

(The TQCC of Liver International is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Issue Information	263
Methylprednisolone‐Induced Liver Injury: Insights From FAERS Analysis and Comparison With DILIN Findings	118
High prevalence of porto‐sinusoidal vascular disease in patients with constantly elevated gamma‐glutamyl transferase levels	110
The Relationship Between TNF‐α Inhibitor Potency and HBV Reactivation in Patients With Rheumatic Disorders	110
Navigating portal hypertension: Unlocking safe passage to healthy pregnancy in EHPVO	109
Cardiac Geometry in Cirrhosis: Translation to Public Health and Trial Design	94
RETRACTION : Interferons α, β, γ Each Inhibit Hepatitis C Virus Replication at the Level of Inte	88
Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT‐FOXO3 signalling pathway	84
Reply: Herbal‐Induced Liver Injury Identification and Prevention	82
Correction to ‘Development and Validation of an Image Biomarker to Identify Metabolic Dysfunction Associated Steatohepatitis: MR‐MASH Score’	82
Immunogenicity and safety of a third dose of anti‐SARS‐CoV‐2 BNT16b2 vaccine in liver transplant recipients	81
Alcohol‐related hepatocellular carcinoma is a heterogenous condition: Lessons from a latent class analysis	72
Frequency of the PNPLA3 rs738409 polymorphism and other genetic loci for liver disease in a Guatemalan adult population	70
Helicobacter pylori‐Associated Surrogate Markers of Intestinal Permeability, Bacterial Translocation and Gut Barrier Damage in Liver Cirrhosis	64
Prognosis of hospitalized patients with cirrhosis and acute kidney disease	64
Hospitalisations With Cryoglobulin‐Related Diseases in Spain Over 25 Years	63
Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort	63
The integrated stress response‐related expression of CHOP due to mitochondrial toxicity is a warning sign for DILI liability	62
Impact of socio‐economic environment on incidence of primary liver cancer in France between 2006 and 2016	61
HBV cure—The light at the end of the tunnel?	59
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease	59
Inside Front Cover	57
Fatty liver disease at the basis of cardiac remodelling and increased heart rate: Insights from the UK Biobank	57
Is ageing a problematic hurdle to the efficacy of first‐line atezolizumab plus bevacizumab in hepatocellular carcinoma?	54
Changing epidemiological features of hepatocellular carcinoma: Taiwan's position	49

Letter to the Editor regarding “Long‐term exposure to air pollution and incident non‐alcoholic fatty liver disease and cirrhosis”	49
Different methodologies of protein induced by vitamin K absence or antagonist II in patients without hepatocellular carcinoma	47
Interpreting elevated liver blood test results through a genetic lens: A genome‐wide association study	46
Issue Cover	46
Think twice about IgG4‐related diseases before operating on hepatic masses	45
Is fresh frozen plasma transfusion associated with outcomes in acute variceal bleeding?	43
Bringing evidence to the MAFLD‐MASLD debate	42
Five‐year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study	41
Time since liver transplant and immunosuppression withdrawal outcomes: Systematic review and individual patient data meta‐analysis	40
Causal effect of lower birthweight on non‐alcoholic fatty liver disease and mediating roles of insulin resistance and metabolites	39
High disease burden and healthcare resource usage in patients with acute porphyria—A population‐based analysis	39
Hepatocytic ballooning in non‐alcoholic steatohepatitis: Dilemmas and future directions	38
Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct‐acting antivirals	38
Association of Liver Disease and Chronic Pruritus: A Case–Control Study	38
Increased platelet ratio in patients with decompensated cirrhosis indicates a higher risk of portal vein thrombosis	38
Benefits of Using cT1 for Risk Stratification in MASLD	37
Importance of gender differences in body composition for liver transplantation and the ‘Sarco‐Model’ study	37
Reply to “Probiotics for Hepatic Encephalopathy Prevention After TIPS : Still an Open Question”	37
Epidemiology and Risk Determinants of Drug‐Induced Liver Injury: Current Knowledge and Future Research Needs	37
Prognostic Role of Endoscopic Ultrasound Guided Direct Portal Pressure Gradient Measurement in Porto‐Sinusoidal Vascular Disorder	36
Golexanolone improves fatigue, motor incoordination and gait and memory in rats with bile duct ligation	35
Determinants of worse liver‐related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort	34
Integrating PNPLA3 into clinical risk prediction	34
A Markov Model Unveiling the Impact of Resmetirom on the Natural History of MASLD Patients: A Sistematic Review and Meta‐Analysis	34
Response to Letter to the Editor: “Chronic Nanoplastic Exposure as a Novel Risk Amplifier for MASLD Progression”	33
On Evaluating GPT ‐4 for CHB Treatment Recommendations: Reproducibility, Vignette Design and Promp	33
Liver Disease Complicating Familial Mediterranean Fever: A Study on 66 Patients Out of 533 Adult From the JIR Cohort	33
Assessment of PBC Pruritus From the ITCH ‐E Study: Quality of Life, Productivity, and Treatment Ex	33
Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy	33
Low‐Level Viremia Impairs Efficacy of Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma	33
TIPS Superiority in Refractory Variceal Haemorrhage: Insights From the TIPSEMS ‐ VB	33
Perilipin 5 protects the mitochondrial oxidative functions and improves the alcoholic liver injury in mice	33
Clarifying Treatment Pathway Differences and Exposure Bias in the CHIEF Cohort Study	32
Bulevirtide for patients with compensated chronic hepatitis delta: A review	32
Gender differences of authors of major Hepatology society guidelines during the past 15 years	32
Letter to the editor regarding “Exploring the landscape of steatotic liver disease in the general US population”	32
Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in Young Children With Chronic HCV Infection	32
Prevalence of metabolic dysfunction‐associated steatotic liver disease in the Middle East and North Africa	32
Hepatic cell junctions: Pulling a double‐duty	31
	31
Case‐based discussion of the acute hepatic porphyrias: Updates on pathogenesis, diagnosis and management	30
Issue Information	30
Autoimmune hepatitis or drug‐induced autoimmune hepatitis following Covid‐19 vaccination?	30
Enhancing the Understanding of Obesity and Liver Health: Addressing Lifestyle, Socio‐economic and Ethnic Disparities	29
¹⁶⁶Ho‐RadioEmbolizaTiOn Using personalized prediCtive dosimetry in patients with Hepatocellular carcinoma: A prospective, single‐centre study (RETOUCH)	29
Response to: Impact of GLP‐1RA on Adverse Liver Outcomes Among Patients With Alcohol‐Associated Liver Disease and Type 2 Diabetes	29
Response to letter from Skouloudi et al	29
Health‐related quality of life in patients with primary sclerosing cholangitis: A longitudinal population‐based cohort study	29
HLA matching between donors and recipients improves clinical liver transplant graft survival	28
Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study	28

Axon guidance molecules in liver pathology: Journeys on a damaged passport	27
Unravelling the Complex Role of Glycine‐Conjugated Bile Acids and Gut‐Liver Axis in Progressive Alcohol‐Related Liver Disease	27
Extracellular vesicles in fatty liver disease and steatohepatitis: Role as biomarkers and therapeutic targets	27
Liver GPBAR1 Associates With Immune Dysfunction in Primary Sclerosing Cholangitis and Its Activation Attenuates Cholestasis in Abcb4−/− Mice	27
Global treatment rate and barriers to direct‐acting antiviral therapy: A systematic review and meta‐analysis of 146 studies and 1 760 352 hepatitis C virus patients	26
Hepatitis D Virus Infection: Pathophysiology, Epidemiology and Treatment. Report From the Third Delta Cure Meeting 2024	26
Red meat intake, faecal microbiome, serum trimethylamine N‐oxide and hepatic steatosis among Chinese adults	26
Autoimmune hepatitis (AIH) following coronavirus (COVID‐19) vaccine—No longer exclusive to mRNA vaccine?	26
Gastrointestinal cancers in lean individuals with non‐alcoholic fatty liver disease: A systematic review and meta‐analysis	26
HERACLIS_BLV_D: Increasing Response Rates During 2‐Year Bulevirtide Real‐Life Therapy in Chronic Hepatitis D	26
An MMP‐degraded and cross‐linked fragment of type III collagen as a non‐invasive biomarker of hepatic fibrosis resolution	26
Sodium–glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use	26
Microvesicle Tissue Factor Procoagulant Activity Is Elevated and Correlated With Disease Severity in Patients With Cirrhosis	26
Outcomes and management in paediatric autoimmune hepatitis presenting as acute liver failure: Individual patient data meta‐analysis	25
Inhibition of MALT1 Protease Attenuates Hepatic Sinusoidal Obstruction Syndrome by Modulating NRF2/HO1 and NF‐κB Pathway	25
Characterization of lymphocyte‐rich hepatocellular carcinoma and the prognostic role of tertiary lymphoid structures	24
Increasing Prevalence of Steatotic Liver Disease in a Japanese Health Checkup Population, 2004–2022	24
Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child–Pugh Class B	24
Multiple arterial‐phase MRI with gadoxetic acid improves diagnosis of hepatocellular carcinoma ≤3.0 cm	24
Patients hospitalized with alcohol‐related liver disease and prior bariatric surgery are more prone to develop acute‐on‐chronic liver failure	24
Myeloid Glutamine Synthetase Protects Against Acute Liver Injury in Mice Independent of Its Enzyme Activity	24
Research gaps and opportunities in autoimmune hepatitis—Results of the international autoimmune hepatitis group research workshop 2022	24
Liver transplantation for autoimmune hepatitis: Pre‐transplant does not predict the early post‐transplant outcome	24
Adding 100 Hz Spleen Stiffness Measurement to the Baveno VII Model Improves Decompensation Risk Pr	23
Role of Gut‐Derived Endotoxins in Porto‐Sinusoidal Vascular Disorder: Comparison Between patients with and without portal hypertension	23
Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated Cirrhosis	23
Blood urea better than creatinine in prognosticating post‐TIPS outcomes: Hope or hype?	22
Nonalcoholic fatty liver disease without overlapping metabolic‐associated fatty liver disease and the risk of incident type 2 diabetes	22
Is it time to get rid of the biopsy mandate in adults with suspected autoimmune hepatitis? Lessons from the COVID‐19 pandemic	22
3‐Mercaptopyruvate sulfurtransferase in hepatocellular carcinoma: Is it an authentic clinical prognostic predictor?	22
Author's reply: Plasma corticosteroid‐binding globulin levels in cirrhosis	22
Appraisal of AI ‐Based Fibrosis Quantification in MASH	22
Enhanced muscle function in cause‐specific mortality among patients with NAFLD‐related sarcopenia	22
Third dose of mRNA COVID‐19 vaccine and response: Correspondence	22
NSBBs, EBL or Combined Therapy for High‐Risk Varices: Systematic Review and Meta‐Analysis	22
Extrahepatic autoimmune diseases do not increase the mortality of autoimmune hepatitis	21
Issue Information	21
How best to combine liver transplantation and bariatric surgery?—Results from a global, web‐based survey	21
Trends in prevalence of probable fibrotic non‐alcoholic steatohepatitis in the United States, 1999–2016	21
Estimated glomerular filtration rate by formulas in patients with cirrhosis: An unreliable procedure	21
Clinical exome sequencing for diagnosing severe cryptogenic liver disease in adults: A case series	21
Predictors of mid‐term survival after liver transplantation in patients with NAFLD cirrhosis	21
Issue Information	21
NAFLD and NASH are obesity‐independent risk factors in COVID‐19: Matched real‐world results from the large PINC AI™ Healthcare Database	21
Issue Information	21
Practical recommendations for biochemical and genetic diagnosis of the porphyrias	20
Treatment and the prognosis of hepatocellular carcinoma in Asia	20
Global trends and the impact of chronic hepatitis B and C on disability‐adjusted life years	20
Digital Histopathology and AI: A New Era of Liver Fibrosis Quantification	20
Hepatic triglyceride content is intricately associated with numerous metabolites and biochemical pathways	20
Comparison of primary liver cancer mortality estimates from World Health Organization, global burden disease and global cancer observatory	20
Immune checkpoint inhibitors in malignancies after liver transplantation: Better safe or sorry?	20
Quality Measures to Enhance the Management and Treatment of Primary Biliary Cholangitis: A Delphi Consensus Study	20
An ultrasound multiparametric method to quantify liver fat using magnetic resonance as standard reference	20
Bcl‐x_L as prognostic marker and potential therapeutic target in cholangiocarcinoma	20
The Global Burden of Cirrhosis and Other Chronic Liver Diseases in 2021	20
Response to Letter to the Editor: “Advancing TMPRSS6‐Targeted Therapy for MASLD: Mechanistic and Translational Perspectives”	20
The changing epidemiology of liver diseases in Asia	20
Determining reinfection rates by hepatitis C testing interval among key populations: A systematic review and meta‐analysis	19
Hepatitis C screening during SARS‐CoV‐2 testing or vaccination. Experience in an area of southern Italy in the province of Salerno	19
Apolipoprotein A‐1 protected hepatic ischaemia–reperfusion injury through suppressing macrophage pyroptosis via TLR4–NF‐κB pathway	19
Issue Information	19
Reply to the letter “Anti‐HBc level predicting virological relapse after stopping nucleos(t)ide analogue in chronic hepatitis B”	19
Featured Cover	19
Alcohol‐related liver disease phenotype impacts survival after an acute variceal bleeding episode	19
Unmet needs in autoimmune hepatitis: Results of the prospective multicentre European Reference Network Registry (R‐LIVER)	19
Issue Information	19
Quality‐of‐life scores improve after 96 weeks of PEG‐IFNa‐2a treatment of hepatitis D: An analysis of the HIDIT‐II trial	19
Regulation of the macrophage‐hepatic stellate cell interaction by targeting macrophage peroxisome proliferator‐activated receptor gamma to prevent non‐alcoholic steatohepatitis progression in mice	19
Prognostic Implications of Cardiac Geometry in Cirrhosis: Findings From a Large Cohort	19
Impairment of Regenerative and Metabolic Pathways in Intestinal Organoids From Patients With MASLD‐Cirrhosis	19
Issue Information	19
Response to Letter to the Editor: ‘Nanoplastics and MASLD : Unveiling Interorgan Crosstalk and Environmental Modulators’	19
Acute Transient Aminotransferase Elevation is Common With Intrathecal Methotrexate, but Liver Injury is Infrequent	18
Ketogenic Diet and Hepatic Ischaemia–Reperfusion Injury: Aggravation or Mitigation?	18
Association of thyroid function with non‐alcoholic fatty liver disease in recent‐onset diabetes	18
Follow‐up post‐HCV virological response to DAA in advanced chronic liver disease	18
Impact of GLP‐1RA on the Risk of Adverse Liver Outcomes Among Patients With Alcohol‐Associated Liver Disease and Type 2 Diabetes	18
Identification of Distinguishing Features of Drug‐Induced Liver Injury and Liver Injury Associated With Sepsis	18
Expanding the donor pool: Kidney transplantation from serum HBV DNA or HBeAg‐positive donors to HBsAg‐negative recipients	18

Bacterial Infections in Severe Alcohol‐Associated Hepatitis: Methodological Considerations	18
The utility of hierarchical genetic testing in paediatric liver disease	18
Alcohol‐related hepatitis admissions increased 50% in the first months of the COVID‐19 pandemic in the USA	18
Refining the Safety Perspective of Bulevirtide in Chronic Hepatitis Delta Management	18
Reply to: Blood urea better than creatinine in prognosticating post‐TIPS outcomes: Hope or hype?	18
Response Letter to: Expanding Perspectives on FIB‐4 as a Predictor of Hepatic and Extrahepatic Malignancy Risk	17
Future anti‐HDV treatment strategies, including those aimed at HBV functional cure	17
Escherichia coli‐derived outer‐membrane vesicles induce immune activation and progression of cirrhosis in mice and humans	17
Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis	17
Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals	17
Determinants of HBsAg Loss After Nucleos(t)ide Discontinuation in a Prospective Cohort of HBeAg ‐N	17
MASLD and MASH Risk: Does Losing Obesity Reverse the Metabolic Footprint	17
Protective role of cGAS in NASH is related to the maintenance of intestinal homeostasis	17
Altered ethanol metabolism and increased oxidative stress enhance alcohol‐associated liver injury in farnesoid X receptor‐deficient mice	17
French guidelines on TIPS: Indications and modalities	17
Outcome of Liver Retransplantation in Patients With Primary Sclerosing Cholangitis	17
Oxidised Apolipoprotein Peptidome Characterises Metabolic Dysfunction‐Associated Steatotic Liver Disease	17
Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook	17
Response to Letter to ‘Serum CRP in Durvalumab‐Tremelimumab‐Treated HCC : Expanding the Inflammato	17
Treatment patterns for hepatocellular carcinoma in patients with Child–Pugh class B and their impact on survival: A Korean nationwide registry study	17
Pilot hepatitis C micro‐elimination strategy in Pakistani migrants in Catalonia through a community intervention	17
Cost of Metabolic Dysfunction‐Associated Steatotic Liver Disease Screening Among All People Living With Diabetes in Six Countries	16
Response to Letter to ‘Serum CRP in Durvalumab–Tremelimumab‐Treated HCC : Expanding the Inflammato	16
	16
Issue Information	16
Front Cover	16
Issue Information	16
SIRT5 Facilitates Liver Steatosis Progression via Promoting SDH Desuccinylation During High‐Fat Diet Feeding	16
Impact of PNPLA3 I148M on Drug‐Induced Hepatocellular Liver Injury: A Systematic Review and Meta‐Analysis	16
Hepatocellular carcinoma: The virus or the liver?	16
Issue Information	16
	16
FBXO31 sensitizes cancer stem cells‐like cells to cisplatin by promoting ferroptosis and facilitating proteasomal degradation of GPX4 in cholangiocarcinoma	16
Elevated Serum Bile Acids Predict Poor Liver Outcomes in Children With Alagille Syndrome: Results From the GALA Study Group	16
Carvedilol as the new non‐selective beta‐blocker of choice in patients with cirrhosis and portal hypertension	16
Fifteen Years of PNPLA3 : Transforming Hepatology Through Human Genetics	16
	16
Issue Information	16
Recipient‐Donor Sex Constellation in Liver Transplantation for Hepatocellular Carcinoma: An ELTR Study — Author Reply	16
Novel insights into metabolic‐associated steatotic liver disease preclinical models	15
The prognostic role of tumour progression and liver function at progression under immunotherapy for hepatocellular carcinoma	15
Histological characterization of liver involvement in systemic mastocytosis	15
Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis	15
Characteristics and outcome of anti‐hepatitis D virus positive patients with hepatocellular carcinoma	15
Autophagy in liver regeneration: Unravelling the endothelial cell's role and therapeutic prospects	15
Global burden of acute hepatitis E between 1990 and 2019 and projections until 2030	15
Response Letter to: Zebrafish: An emerging and expedient model for liver studies?	15
Response to: Letter to the Editor “Child‐Turcotte‐Pugh score as a model for organ allocation in liver transplantation, perhaps old is still gold”	15
Stenting of ductus venosus as a palliation for portal hypertension because of neonatal cirrhosis	15
MASLD And MASH Risk: Does Losing Obesity Reverse the Metabolic Footprint?	15
Overcoming the challenges of eliminating viral hepatitis in low‐ and middle‐income countries	15
Inside Front Cover	15
PRO‐C3, liver fibrosis and CKD: The plot thickens	15
	15
Sweating it out: How physical activity can combat high genetic risk for nonalcoholic fatty liver disease	15
Impact of sarcopenia on postoperative outcomes after hepatectomy in older patients with intrahepatic cholangiocarcinoma: A multicentre cohort study	15
Trajectories of glycaemic traits exhibit sex‐specific associations with hepatic iron and fat content: Results from the KORA‐MRI study	15
Acute alcohol‐associated hepatitis: Latest findings in non‐invasive biomarkers and treatment	15
Preoperative magnetic resonance imaging‐based prognostic model for mass‐forming intrahepatic cholangiocarcinoma	15
Leflunomide‐induced liver injury: Differences in characteristics and outcomes in Indian and US registries	15
Management of alcoholic hepatitis: A clinical perspective	14
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease	14
Nuclear translocation of YAP drives BMI‐associated hepatocarcinogenesis in hepatitis B virus infection	14
Hepatitis Delta: Ready for primetime?	14
PNPLA3 variation and kidney disease	14
	14
scRNA ‐Seq Reveals Sustained Pro‐Inflammation by Innate Immune Activation in In Utero HBV‐ Exposed Neonates of High	14
Transjugular intrahepatic portosystemic shunt for portal hypertension: 30 years experience from China	14
Epidemiology and surveillance of autoimmune hepatitis in Asia	14
From Creatinine Cut‐Offs to Bedside Precision: A Road‐Map for Safer Terlipressin in Early Hepatorenal Syndrome	14
A Transformer‐Based microvascular invasion classifier enhances prognostic stratification in HCC following radiofrequency ablation	14
Response Letter to: Association of thyroid function with nonalcoholic fatty liver disease in recent‐onset diabetes	14
The Relationship Between Ferroptosis and Metabolic Dysfunction‐Associated Fatty Liver Disease	14
Deficient chaperone‐mediated autophagy in macrophage aggravates inflammation of nonalcoholic steatohepatitis by targeting Nup85	14
Response to: “The Role of Platelets in MASLD : From Mechanisms to Clinical Implications”	14
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma	14
Free Testosterone Is Associated With Worse Survival in Patients With Advanced Chronic Liver Disease Awaiting Liver Transplantation	14
Efficacy and safety of percutaneous cryoablation for elderly patients with small hepatocellular carcinoma: A prospective multicenter study	14
Inhibition of IRE‐1α Alleviates Pyroptosis and Metabolic Dysfunction‐Associated Steatohepatitis by Suppressing Gasdermin D	14
Protective effects of statins on the incidence of NAFLD–related decompensated cirrhosis in T2DM	14
CD44 in Group 1 Innate Lymphoid Cells Impacts the Development and Progression of Steatohepatitis	14
Zebrafish: An emerging and expedient model for liver studies?	14
Delta virus infection and hepatocellular carcinoma	14
Optimizing large language models in digestive disease: strategies and challenges to improve clinical outcomes	14
A Novel Score for Predicting Long‐Term Outcomes in Recanalisation‐Treated Patients With Budd‐Chiari Syndrome: A Multicentre Study	14
Interpreting the Clinical Significance of Spleen Stiffness in Baveno VII Risk Stratification	14
Evaluating the Long‐Term Benefits of Medications for Alcohol Use Disorder in Alcohol‐Associated Cirrhosis	14
Molecular mechanism of albumin in suppressing invasion and metastasis of hepatocellular carcinoma	14
Mitochondrial amidoxime‐reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome	14
The Depletion of Plasma Cells but Not CD20 ⁺ B Cells Alleviates Primary Biliary Cholangitis	13
Beneficial effects of hepatic cyclooxygenase‐2 expression against cholestatic injury after common bile duct ligation in mice	13
Not So Quiet on the Viral Front: Low‐Level HBV Viraemia Undermines Immunotherapy in HCC	13
Navigating the Hepatic Immune Landscape With Fine Needle Aspiration of the Liver—An Emerging Technique	13
Exosome‐derived miR‐182‐5p promoted cholangiocarcinoma progression and vasculogenesis by regulating ADK/SEMA5a/PI3K pathway	13
Mortality and Cancer in Offspring of Mothers With Biopsy‐Proven MASLD During Pregnancy: A Nationwide Cohort Study	13